Novavax, Inc. NVAX shares are trading lower by 6.76% to $32.84 Wednesday afternoon in possible reaction to competitor Moderna Inc MRNA receiving FDA authorization for emergency use of its Omicron-targeting COVID-19 booster. Pfizer Inc. PFE and BioNTech SE - ADR BNTX were also granted Emergency Use Authorization for their BA.4/BA.5-adapted Bivalent COVID-19 booster.
What Else?
Moderna Wednesday announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222.
Authorization has been given for a 50 µg booster dose for adults over 18 years of age who have received either a primary series or an initial booster of any of the authorized or approved COVID-19 vaccines.
The 50 µg booster dose of mRNA-1273.222 includes 25 µg of mRNA encoding for the spike protein of BA.4/.5 and 25 µg encoding for the original strain of the SARS-CoV-2 virus.
Meanwhile, Pfizer and BioNTech Wednesday announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original [15 µg] and Omicron BA.4/BA.5 [15 µg]) for individuals ages 12 years and older.
An application for an Omicron-adapted bivalent vaccine for children 5 through 11 years of age is planned for submission to FDA in early October.
The companies are working with the FDA to prepare an application for an Omicron-adapted bivalent vaccine in children 6 months through 4 years of age.
See Also: Why Pinterest Shares Are On The Move Today
According to data from Benzinga Pro, Novavax has a 52-week high of $277.80 and a 52-week low of $32.62.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
